Capital Advisors Inc. OK Has $5.22 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Capital Advisors Inc. OK raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,318 shares of the company's stock after acquiring an additional 892 shares during the quarter. Capital Advisors Inc. OK's holdings in Eli Lilly and Company were worth $5,218,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. grew its position in shares of Eli Lilly and Company by 17.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,112,001 shares of the company's stock worth $918,413,000 after buying an additional 161,665 shares during the period. Drake & Associates LLC grew its position in shares of Eli Lilly and Company by 15.4% during the 1st quarter. Drake & Associates LLC now owns 846 shares of the company's stock worth $699,000 after buying an additional 113 shares during the period. Crew Capital Management Ltd. grew its position in shares of Eli Lilly and Company by 7.1% during the 1st quarter. Crew Capital Management Ltd. now owns 1,127 shares of the company's stock worth $931,000 after buying an additional 75 shares during the period. Tradewinds LLC. grew its position in shares of Eli Lilly and Company by 3.7% during the 1st quarter. Tradewinds LLC. now owns 6,002 shares of the company's stock worth $4,957,000 after buying an additional 215 shares during the period. Finally, Cloud Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $54,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.4%

LLY traded up $18.18 during trading hours on Tuesday, hitting $791.05. 804,145 shares of the company's stock were exchanged, compared to its average volume of 3,652,613. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock's 50-day moving average is $771.52 and its two-hundred day moving average is $800.30. The stock has a market cap of $749.70 billion, a price-to-earnings ratio of 64.36, a PEG ratio of 1.14 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.